vedolizumab subcutaneous — Medica

Initial criteria

• age ≥ 18 years
• According to the prescriber, the patient is currently receiving Entyvio intravenous or will receive induction dosing with Entyvio intravenous within 2 months of initiating therapy with Entyvio subcutaneous
• The medication is prescribed by or in consultation with a gastroenterologist

Reauthorization criteria

• Patient has been established on Entyvio subcutaneous or intravenous for at least 6 months
• Patient meets at least ONE of the following: a) When assessed by at least one objective measure, patient experienced a beneficial clinical response from baseline (examples: fecal calprotectin, C-reactive protein, endoscopic assessment, or reduced corticosteroid dose); OR b) Compared with baseline, patient experienced improvement in at least one symptom such as decreased pain, fatigue, stool frequency, and/or decreased rectal bleeding

Approval duration

initial: 6 months; reauthorization: 1 year